Hongcheng Zhu, Radiation Oncologist at Fudan University Shanghai Cancer Center, shared a post on LinkedIn about a paper he co-authored with colleagues published in Clinical and Translational Radiation Oncology:
“Old dog, new tricks! Our newly published ESO-Shanghai 17 trial reported a feasible and safe postoperative chemoradiotherapy regime in ESCC, providing an alternative approach for those who didn’t receive neoadjuvant therapies before surgery.”
Title: Postoperative chemoradiotherapy for esophageal squamous cell Carcinoma: Results from ESO-Shanghai 17 and joint analyses for phase II clinical trials
Authors: Jingyi Shen, Dashan Ai, Yun Chen, Qi Liu, Jiaying Deng, Shengnan Hao, Xiaofei Zhang, Junhua Zhang, Yutong Zhang, Li Chu, Yihua Sun, Yawei Zhang, Jiaqing Xiang, Longsheng Miao, Haiquan Chen, Hongcheng Zhu, and Kuaile Zhao
You can read the Full Article in Clinical and Translational Radiation Oncology.
More posts featuring Hongcheng Zhu.